Skip to content

Speaking Valve Trial vs. Capping Trial for Tracheostomy Decannulation in Prolonged Disorders of Consciousness

Comparison of Speaking Valve Trial Versus Capping Trial in the Decannulation Process for Patients With Prolonged Disorders of Consciousness: A Randomized Controlled Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07173634
Acronym
SPEAK-CAP
Enrollment
280
Registered
2025-09-15
Start date
2026-02-01
Completion date
2027-05-01
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolonged Disorders of Consciousness

Keywords

Prolonged disorders of consciousness, Decannulation, Speaking wave, Capping, Rehabilitation

Brief summary

To assess whether the speaking valve trial, when employed as an indicator for extubation during the removal of tracheostomy tubes in patients with chronic consciousness disorder, provides superior benefits and heightened sensitivity relative to the conventional capping trial, thereby enhancing the overall extubation process.

Detailed description

Patients with chronic consciousness disorder who require long-term mechanical ventilation and airway protection commonly undergo tracheostomy. However, tracheostomy tubes can cause inflammation, stenosis, excessive coughing, and swallowing dysfunction. Removing the tracheostomy tube, or extubation, can prevent long-term complications such as tracheal stenosis, tracheomalacia, vocal cord injury, and accidental extubation. Additionally, it enhances patient comfort, appearance, swallowing function, communication ability, and social integration. Therefore, for clinically stable patients with chronic consciousness disorder who can breathe spontaneously, have effective cough reflexes, and are capable of protecting their airways, early tube removal is advisable.In current extubation protocols, the capping trial is predominantly used to assess whether patients can tolerate tracheostomy tube removal. There have also been reports of studies using speaking valves as an alternative to the capping trial, but no direct comparison has been made between the two methods. Patients who can tolerate capping for 24 hours are generally considered suitable for tracheostomy tube removal. A speaking valve is a one-way valve placed at the end of the tracheostomy tube that directs airflow to the upper airway when the cuff is deflated. Studies have found that patients undergoing speaking valve training benefit in terms of vital signs, airway secretions, sense of smell, weaning from mechanical ventilation, post-tracheostomy extubation, hospital stay duration, and quality of life. However, it remains unclear whether this method can improve the success rate of extubation assessment in patients with chronic consciousness disorder. This study compares speaking valve training and the traditional capping trial in post-tracheostomy patients with chronic consciousness disorder, evaluating differences in extubation tolerance, extubation success rate, time to extubation, hospital stay duration, and improvement in consciousness levels. Parazacco spilurus subsp. spilurus

Interventions

OTHERSpeaking Valve Trial

The speaking valve group ascertains a patient's eligibility for decannulation following the results of the speaking valve test. A patient who can endure a 4-hour trial with a speaking valve, maintaining a pulse oxygen saturation (SpO₂) of at least 95%, a breathing rate (RR) below 20 per minute, and exhibiting no signs of distress throughout the trial, qualifies for decannulation.

The capping valve group determines a patient's eligibility for decannulation based on the results of the capping test. A patient who can tolerate 48 hours of capping with a pulse oxygen saturation (SpO₂) of ≥95%, a breathing rate (RR) of \<20/min, and no signs of distress during the 48-hour trial, is eligible for decannulation.

Sponsors

Hongying Jiang, MD
Lead SponsorOTHER
Beijing Rehabilitation Hospital
CollaboratorOTHER
Beijing Tiantan Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Adults (18-80 years) with tracheostomy 2. Prolonged DoC (\>28 days) confirmed by CRS-R score \>0 3. Ventilator-free \>48h 4. PaCO₂ \<60 mmHg 5. PCF ≥100 L/min 6. No sepsis/organ failure 7. Controlled pulmonary infection 8. Written informed consent by legal representative

Exclusion criteria

1. Intolerance to cuff deflation: 2. SpO₂ \<93% on O₂ supplementation OR Respiratory rate \>20/min for \>5min 3. Severe tracheal stenosis (\>50% lumen occlusion on CT) 4. Death within 2 weeks post-enrollment 5. Participation in conflicting interventional trial

Design outcomes

Primary

MeasureTime frameDescription
Decannulation rateAt decannulationProportion passing full protocol
Decannulation success rateAt 48 h post decannulation(Decannulation - Decannulation failure ) / Decannulation

Secondary

MeasureTime frameDescription
Time to decannulation1yearDays from randomization to successful tube removal
Hospital stay durationUp to 6 monthsDays from randomization to discharge without tracheostomy care
CRS-R change rate3 months(Post-decannulation score - Baseline)/Baseline
Airway safety score148h post-decannulationPulse oxygen saturation (SpO₂) fluctuation, minimum value0%, maximum value 100%, the larger the value, the better the result
Airway safety score 248h post-decannulationBlood carbon dioxide partial pressure (pCO₂) , normal range 35-45mmHg. Within the normal range it is good, the greater the deviation from the normal range, the worse the result the larger the value, the better the result.

Countries

China

Contacts

STUDY_CHAIRHongying Jiang

Beijing Rehabilitation Hospital, Capital Medical University, Beijing

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026